IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City.
Piper Sandler 36th Annual Healthcare Conference
Fireside discussion: Wednesday, December 4, 3:00-3:25 pm ET
Webcast: https://event.webcasts.com/starthere.jsp?ei=1699716&tp_key=9f5393d579
A live webcast of the fireside chat will be accessible on the Investor page of mdxhealth’s website at https://mdxhealth.com/presentations-events/. Replays will be available for up to 60 days following each event.
About mdxhealth®
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
This email address is being protected from spambots. You need JavaScript enabled to view it.
LifeSci Advisors (IR & PR)
US: +1 949 271 9223
This email address is being protected from spambots. You need JavaScript enabled to view it.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Last Trade: | US$1.60 |
Daily Change: | 0.06 3.56 |
Daily Volume: | 15,252 |
Market Cap: | US$79.200M |
February 26, 2025 February 12, 2025 January 13, 2025 November 06, 2024 October 14, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load